Share

April 18, 2017; 88 (16 Supplement) April 27, 2017

High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a) (S44.005)

Raymond Hupperts, Joost Smolders, Reinhard Vieth, Trygve Holmøy, Kurt Marhardt, Myriam Schluep, Joep Killestein, Frederik Barkhof, Luigi Maria Grimaldi, Manolo Beelke
First published April 17, 2017,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 88 no. 16 Supplement S44.005
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 17, 2017.
Copyright & Usage: 
© 2017

Author Disclosures

    1. Raymond Hupperts1,
    2. Joost Smolders2,3,
    3. Reinhard Vieth3,
    4. Trygve Holmøy4,
    5. Kurt Marhardt5,
    6. Myriam Schluep6,
    7. Joep Killestein7,
    8. Frederik Barkhof8,9,
    9. Luigi Maria Grimaldi10 and
    10. Manolo Beelke11
  1. Raymond Hupperts1,
  2. Joost Smolders2,3,
  3. Reinhard Vieth3,
  4. Trygve Holmøy4,
  5. Kurt Marhardt5,
  6. Myriam Schluep6,
  7. Joep Killestein7,
  8. Frederik Barkhof8,9,
  9. Luigi Maria Grimaldi10 and
  10. Manolo Beelke11
  1. 1Orbis Medisch Centrum, Maastricht University Medical Center Sittard Netherlands
  2. 2Canisus Wilhelmina Ziekenhuis Nijmegen Netherlands
  3. 3University of Toronto Nijmegen Netherlands
  4. 4Akershus University Hospital and University of Oslo Oslo Norway
  5. 5Merck GmbH Vienna Austria
  6. 6Service de Neurologie, Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
  7. 7Department of Neurology, VU University Medical Centre Amsterdam Netherlands
  8. 8Radiology and Nuclear Medicine, VU University Medical Centre Amsterdam Netherlands
  9. 9Institutes of Neurology & Healthcare Engineering, University College London Amsterdam Netherlands
  10. 10U.O.C. Neurologia and Multiple Sclerosis Center, Fondazione Istituto G. Giglio di Cefalù Cefalù Italy
  11. 11Worldwide Clinical Trials GmbH Germering Germany

Article usage

Article usage: April 2017 to April 2022

AbstractFullPdfSource
Apr 20173200Highwire
May 201710600Highwire
Jun 20172600Highwire
Jul 20175400Highwire
Aug 20174600Highwire
Sep 20174200Highwire
Oct 20175200Highwire
Nov 20173000Highwire
Dec 20173200Highwire
Jan 20185100Highwire
Feb 20182800Highwire
Mar 20182200Highwire
Apr 20183500Highwire
May 20184900Highwire
Jun 20181500Highwire
Jul 20182400Highwire
Aug 20181900Highwire
Sep 20181600Highwire
Oct 20182900Highwire
Nov 20182100Highwire
Dec 20181300Highwire
Jan 20193200Highwire
Feb 20192100Highwire
Mar 20192100Highwire
Apr 20192000Highwire
May 20191500Highwire
Jun 20192200Highwire
Jul 20191400Highwire
Aug 20191200Highwire
Sep 20191800Highwire
Oct 20192600Highwire
Nov 20192200Highwire
Dec 20192400Highwire
Jan 2020700Highwire
Feb 20201900Highwire
Mar 20201700Highwire
Apr 2020900Highwire
May 20201500Highwire
Jun 20201200Highwire
Jul 2020600Highwire
Aug 2020400Highwire
Sep 20201600Highwire
Oct 20201100Highwire
Nov 20201200Highwire
Dec 20201100Highwire
Jan 20211000Highwire
Feb 2021400Highwire
Mar 20211000Highwire
Apr 2021300Highwire
May 2021600Highwire
Jun 2021700Highwire
Jul 2021600Highwire
Aug 2021800Highwire
Sep 2021700Highwire
Oct 2021600Highwire
Nov 2021900Highwire
Dec 2021800Highwire
Jan 2022700Highwire
Feb 2022300Highwire
Mar 2022300Highwire
Apr 20221200Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me